" class="no-js "lang="en-US"> Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom - Medtech Alert
Saturday, December 14, 2024

Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom

Moderna, Inc . (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement in principle with the United Kingdom government to establish an mRNA Innovation and Technology Center in the UK. This state-of-the-art mRNA vaccine manufacturing facility is expected to provide access to rapid pandemic response capabilities and Moderna’s respiratory virus vaccine candidates. Additionally, Moderna plans to expand its presence in the UK through investments in research and development (R&D) activities.

“We are excited to be able to continue our collaboration with the UK government and Vaccine Taskforce with this new mRNA Innovation and Technology Center in the UK. The UK has established a world-class life sciences and research community,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We are committed to global public health, and as we continue to expand internationally, we are pleased to bring local mRNA manufacturing to the UK. We look forward to establishing our R&D activities and capabilities in the country.”

Moderna is committed to working with governments, health care professionals, and other key stakeholders to meet the challenges of the COVID-19 pandemic and future pathogens. Moderna expects its state-of-the-art manufacturing facility to produce mRNA vaccines, including vaccines against COVID-19, seasonal influenza, respiratory syncytial virus (RSV), and potential other vaccines, with the collaboration of the United Kingdom government.

The facility is intended to also be activated on an urgent basis to support the UK with direct access to rapid pandemic response capabilities and will support the UK in its global efforts as part of its “100 Days Mission” to reduce the impact of future pandemics.

The Company plans to expand its presence in the UK through investments in R&D to complement its substantial global R&D activities. Moderna is collaborating with the National Institute for Health Research (NIHR) on a Phase 3 study investigating Moderna’s bivalent Omicron-containing booster candidate (mRNA-1273.214) in the UK.

Separately, the UK government purchased 60 million doses of Moderna’s COVID-19 vaccine, which may include authorized booster vaccine candidates for delivery in 2022 and 2023.

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more